These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
132 related articles for article (PubMed ID: 16393913)
1. TT232, a novel signal transduction inhibitory compound in the therapy of cancer and inflammatory diseases. Szokolóczi O; Schwab R; Peták I; Orfi L; Pap A; Eberle AN; Szüts T; Kéril G J Recept Signal Transduct Res; 2005; 25(4-6):217-35. PubMed ID: 16393913 [TBL] [Abstract][Full Text] [Related]
2. Somatostatin analogs for diagnosis and treatment of cancer. Weckbecker G; Raulf F; Stolz B; Bruns C Pharmacol Ther; 1993 Nov; 60(2):245-64. PubMed ID: 7912834 [TBL] [Abstract][Full Text] [Related]
3. Pharmacological characterisation of the somatostatin analogue TT-232: effects on neurogenic and non-neurogenic inflammation and neuropathic hyperalgesia. Pintér E; Helyes Z; Németh J; Pórszász R; Pethö G; Thán M; Kéri G; Horváth A; Jakab B; Szolcsányi J Naunyn Schmiedebergs Arch Pharmacol; 2002 Aug; 366(2):142-50. PubMed ID: 12122501 [TBL] [Abstract][Full Text] [Related]
4. Characterization of the intracellular mechanisms mediating somatostatin and lanreotide inhibition of DNA synthesis and growth hormone release from dispersed human GH-secreting pituitary adenoma cells in vitro. Florio T; Thellung S; Corsaro A; Bocca L; Arena S; Pattarozzi A; Villa V; Massa A; Diana F; Schettini D; Barbieri F; Ravetti JL; Spaziante R; Giusti M; Schettini G Clin Endocrinol (Oxf); 2003 Jul; 59(1):115-28. PubMed ID: 12807513 [TBL] [Abstract][Full Text] [Related]
5. The antitumor somatostatin analogue TT-232 induces cell cycle arrest through PKCdelta and c-Src. Steták A; Lankenau A; Vántus T; Csermely P; Ullrich A; Kéri G Biochem Biophys Res Commun; 2001 Jul; 285(2):483-8. PubMed ID: 11444868 [TBL] [Abstract][Full Text] [Related]
7. TT-232: a somatostatin structural derivative as a potent antitumor drug candidate. Szende B; Kéri G Anticancer Drugs; 2003 Sep; 14(8):585-8. PubMed ID: 14501379 [TBL] [Abstract][Full Text] [Related]
8. Antitumor activity of the somatostatin structural derivative (TT-232), against mouse and human melanoma tumor models. Tejeda M; Gaál D; Hullán L; Schwab R; Szokoloczi O; Kéri G Anticancer Res; 2007; 27(6B):4015-9. PubMed ID: 18225564 [TBL] [Abstract][Full Text] [Related]
9. Somatostatin and its receptor family. Patel YC Front Neuroendocrinol; 1999 Jul; 20(3):157-98. PubMed ID: 10433861 [TBL] [Abstract][Full Text] [Related]
10. Somatostatin stimulates the migration of hepatic oval cells in the injured rat liver. Jung Y; Oh SH; Witek RP; Petersen BE Liver Int; 2012 Feb; 32(2):312-20. PubMed ID: 22098068 [TBL] [Abstract][Full Text] [Related]
11. Antiproliferative activity induced by the somatostatin analogue, TT-232, in human pancreatic cancer cells. Lee JU; Hosotani R; Wada M; Doi R; Koshiba T; Fujimoto K; Miyamoto Y; Tsuji S; Nakajima S; Hirohashi M; Uehara T; Arano Y; Fujii N; Imamura M Eur J Cancer; 2002 Jul; 38(11):1526-34. PubMed ID: 12110500 [TBL] [Abstract][Full Text] [Related]
12. Novel antitumor peptide hormones and their effect on signal transduction. Kéri G; Balogh A; Horváth A; Mezö I; Vadász Z; Bökönyi G; Bajor T; Vántus T; Teplán I; Horváth J J Steroid Biochem Mol Biol; 1992 Sep; 43(1-3):105-10. PubMed ID: 1356011 [TBL] [Abstract][Full Text] [Related]
13. Stimulation of tyrosine phosphatase and inhibition of cell proliferation by somatostatin analogues: mediation by human somatostatin receptor subtypes SSTR1 and SSTR2. Buscail L; Delesque N; Estève JP; Saint-Laurent N; Prats H; Clerc P; Robberecht P; Bell GI; Liebow C; Schally AV Proc Natl Acad Sci U S A; 1994 Mar; 91(6):2315-9. PubMed ID: 7907795 [TBL] [Abstract][Full Text] [Related]
14. Inhibition of cell proliferation by the somatostatin analogue RC-160 is mediated by somatostatin receptor subtypes SSTR2 and SSTR5 through different mechanisms. Buscail L; Estève JP; Saint-Laurent N; Bertrand V; Reisine T; O'Carroll AM; Bell GI; Schally AV; Vaysse N; Susini C Proc Natl Acad Sci U S A; 1995 Feb; 92(5):1580-4. PubMed ID: 7878022 [TBL] [Abstract][Full Text] [Related]
15. Anti-inflammatory effect of synthetic somatostatin analogues in the rat. Helyes Z; Pintér E; Németh J; Kéri G; Thán M; Oroszi G; Horváth A; Szolcsányi J Br J Pharmacol; 2001 Dec; 134(7):1571-9. PubMed ID: 11724765 [TBL] [Abstract][Full Text] [Related]
16. Experience with indium-111 and yttrium-90-labeled somatostatin analogs. Virgolini I; Traub T; Novotny C; Leimer M; Füger B; Li SR; Patri P; Pangerl T; Angelberger P; Raderer M; Burggasser G; Andreae F; Kurtaran A; Dudczak R Curr Pharm Des; 2002; 8(20):1781-807. PubMed ID: 12171531 [TBL] [Abstract][Full Text] [Related]
17. Cloned somatostatin receptors: identification of subtype-selective peptides and demonstration of high affinity binding of linear peptides. Raynor K; Murphy WA; Coy DH; Taylor JE; Moreau JP; Yasuda K; Bell GI; Reisine T Mol Pharmacol; 1993 Jun; 43(6):838-44. PubMed ID: 8100350 [TBL] [Abstract][Full Text] [Related]
19. Somatostatin receptors in non-neuroendocrine malignancies: the potential role of somatostatin analogs in solid tumors. Hasskarl J; Kaufmann M; Schmid HA Future Oncol; 2011 Jul; 7(7):895-913. PubMed ID: 21732759 [TBL] [Abstract][Full Text] [Related]
20. The antitumor activity of the somatostatin structural derivative (TT-232) on different human tumor xenografts. Tejeda M; Gaal D; Barna K; Csuka O; Kéri G Anticancer Res; 2003; 23(5A):4061-6. PubMed ID: 14666719 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]